Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Acute Myeloid Leukemia | Research

High HSPA8 expression predicts adverse outcomes of acute myeloid leukemia

Authors: Jun Li, Zheng Ge

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Acute myeloid leukemia (AML) remains one of the most common hematological malignancies, posing a serious challenge to human health. HSPA8 is a chaperone protein that facilitates proper protein folding. It contributes to various activities of cell function and also is associated with various types of cancers. To date, the role of HSPA8 in AML is still undetermined.

Methods

In this study, public datasets available from the TCGA (Cancer Genome Atlas) and GEO (Gene Expression Omnibus) were mined to discover the association between the expression of HSPA8 and clinical phenotypes of CN-AML. A series of bioinformatics analysis methods, including functional annotation and miRNA-mRNA regulation network analysis, were employed to investigate the role of HSPA8 in CN-AML.

Results

HSPA8 was highly expressed in the AML patients compared to the healthy controls. The high HSPA8 expression had lower overall survival (OS) rate than those with low HSPA8 expression. High expression of HSPA8 was also an independent prognostic factor for overall survival (OS) of CN-AML patients by multivariate analysis. The differential expressed genes (DEGs) associated with HSPA8 high expression were identified, and they were enriched PI3k-Akt signaling, cAMP signaling, calcium signaling pathway. HSPA8 high expression was also positively associated with micro-RNAs (hsa-mir-1269a, hsa-mir-508-3p, hsa-mir-203a), the micro-RNAs targeted genes (VSTM4, RHOB, HOBX7) and key known oncogenes (KLF5, RAN, and IDH1), and negatively associated with tumor suppressors (KLF12, PRKG1, TRPS1, NOTCH1, RORA).

Conclusions

Our research revealed HSPA8 as a novel potential prognostic factor to predict the survival of CN-AML patients. Our data also revealed the possible carcinogenic mechanism and the complicated microRNA-mRNA network associated with the HSPA8 high expression in AML.

Available only for authorised users

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–74. https://doi.org/10.1056/NEJMoa1301689.

Büchner T, Hiddemann W, Schoch C, Haferlach T, Sauerland M-C, Heinecke A. Acute myeloid leukaemia (AML): treatment of the older patient. Best Pract Res Clin Haematol. 2001;14(1):139–51. https://doi.org/10.1053/beha.2000.0120.CrossRefPubMed

Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer. 2006;106(5):1090–8. https://doi.org/10.1002/cncr.21723.CrossRefPubMed

Shaffer BC, Gillet J-P, Patel C, Baer MR, Bates SE, Gottesman MM. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat. 2012;15(1-2):62–9. https://doi.org/10.1016/j.drup.2012.02.001.CrossRefPubMedPubMedCentral

Raponi M, Lancet JE, Fan H, et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood. 2008;111:2589–96.CrossRef

Raponi M, Harousseau J-L, Lancet JE, et al. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res. 2007;13:2254–60.CrossRef

Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006;31:164–72.CrossRef

Urquhart KR, Zhao Y, Baker JA, et al. A novel heat shock protein alpha 8 (Hspa8) molecular network mediating responses to stress- and ethanol-related behaviors. Neurogenetics. 2016;17:91–105.CrossRef

Nirdé P, Derocq D, Maynadier M, et al. Heat shock cognate 70 protein secretion as a new growth arrest signal for cancer cells. Oncogene. 2010;29:117–27.CrossRef

10.

Metzeler KH, Hummel M, Bloomfield CD, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008;112:4193–201.CrossRef

11.

Lilljebjörn H, Heidenblad M, Nilsson B, et al. Combined high-resolution array-based comparative genomic hybridization and expression profiling of ETV6/RUNX1-positive acute lymphoblastic leukemias reveal a high incidence of cryptic Xq duplications and identify several putative target genes within the commonly gained region. Leukemia. 2007;21:2137–44.CrossRef

12.

Stirewalt DL, Meshinchi S, Kopecky KJ, et al. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer. 2008;47:8–20.CrossRef

13.

Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.CrossRef

14.

Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Köntgen F, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286(5445):1735–8. https://doi.org/10.1126/science.286.5445.1735.CrossRefPubMed

15.

Xiang X, You X-M, Li L-Q. Expression of HSP90AA1/HSPA8 in hepatocellular carcinoma patients with depression. Onco Targets Ther. 2018;11:3013–23. https://doi.org/10.2147/OTT.S159432.CrossRefPubMedPubMedCentral

16.

Shan N, Zhou W, Zhang S, Zhang Y. Identification of HSPA8 as a candidate biomarker for endometrial carcinoma by using iTRAQ-based proteomic analysis. Onco Targets Ther. 2016;9:2169–79. https://doi.org/10.2147/OTT.S97983.CrossRefPubMedPubMedCentral

17.

Tian Y, Xu H, Farooq AA, Nie B, Chen X, Su S, et al. Maslinic acid induces autophagy by down-regulating HSPA8 in pancreatic cancer cells. Phytother Res. 2018;32(7):1320–31. https://doi.org/10.1002/ptr.6064.CrossRefPubMed

18.

José-Enériz ES, Román-Gómez J, Cordeu L, Ballestar E, Gárate L, Andreu EJ, et al. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia. Br J Haematol. 2008;142(4):571–82. https://doi.org/10.1111/j.1365-2141.2008.07221.x.CrossRefPubMed

19.

Woo JA, Liu T, Zhao X, Trotter C, Yrigoin K, Cazzaro S, et al. Enhanced tau pathology via RanBP9 and Hsp90/Hsc70 chaperone complexes. Hum Mol Genet. 2017;26(20):3973–88. https://doi.org/10.1093/hmg/ddx284.CrossRefPubMedPubMedCentral

20.

Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA, Kersey JH. FLT3 expressing Leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res. 2003;9:4483.PubMed

21.

Herschbein L, Liesveld JL. Dueling for dual inhibition: means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML. Blood Rev. 2018;32(3):235–48. https://doi.org/10.1016/j.blre.2017.11.006.CrossRefPubMed

22.

Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, et al. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. Oncogene. 2016;35(39):5119–31. https://doi.org/10.1038/onc.2016.41.CrossRefPubMedPubMedCentral

23.

Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2010;95(5):819–28. https://doi.org/10.3324/haematol.2009.013797.CrossRefPubMed

24.

Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs. 2009;18(9):1333–49. https://doi.org/10.1517/14728220903136775.CrossRefPubMed

25.

Chen Y-F, Chen Y-T, Chiu W-T, Shen M-R. Remodeling of calcium signaling in tumor progression. J Biomed Sci. 2013;20(1):23. https://doi.org/10.1186/1423-0127-20-23.CrossRefPubMedPubMedCentral

26.

Jin RH, Yu DJ, Zhong M. MiR-1269a acts as an onco-miRNA in non-small cell lung cancer via down-regulating SOX6. Eur Rev Med Pharmacol Sci. 2018;22(15):4888–97. https://doi.org/10.26355/eurrev_201808_15625.CrossRefPubMed

27.

Zhao L, Wang W, Xu L, Yi T, Zhao X, Wei Y, et al. Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer. Oncogene. 2019;38(13):2305–19. https://doi.org/10.1038/s41388-018-0577-5.CrossRefPubMed

28.

Chen L, Gao H, Liang J, Qiao J, Duan J, Shi H, et al. miR-203a-3p promotes colorectal cancer proliferation and migration by targeting PDE4D. Am J Cancer Res. 2018;8(12):2387–401.PubMedPubMedCentral

29.

Martina P, Matteo Z, Tregnago C, et al. Rhob overexpression boosts relapse of t(8;21) RUNX1-RUNX1T1 rearranged acute myeloid leukemia. Blood. 2017;130:1192.

30.

Wang J, Manick B, Renelt M, et al. VSTM4 is a novel negative regulator of T cell activation. J Immunol. 2019;202:124.4.

31.

Errico MC, Jin K, Sukumar S, Carè A. The widening sphere of influence of HOXB7 in solid tumors. Cancer Res. 2016;76(10):2857–62. https://doi.org/10.1158/0008-5472.CAN-15-3444.CrossRefPubMedPubMedCentral

32.

Chen JQ, Bao Y, Litton J, Xiao L, Zhang HZ, Warneke CL, et al. Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer. Horm Cancer. 2011;2(2):132–43. https://doi.org/10.1007/s12672-011-0067-5.CrossRefPubMed

33.

Vicente C, Vazquez I, Conchillo A, García-Sánchez MA, Marcotegui N, Fuster O, et al. Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities. Leukemia. 2012;26(3):550–4. https://doi.org/10.1038/leu.2011.235.CrossRefPubMed

34.

Snider C, Fung K, Gould F, et al. RORA is a potential prognostic biomarker and therapeutic target for patients with acute myeloid leukemia. Blood. 2019;134:2696.CrossRef

35.

Hindson CM, Chevillet JR, Briggs HA, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 2013;10:1003–5.CrossRef

36.

Huggett JF, Whale A. Digital PCR as a novel technology and its potential implications for molecular diagnostics. Clin Chem. 2013;59(12):1691–3.

Title: High HSPA8 expression predicts adverse outcomes of acute myeloid leukemia
Authors: Jun Li
Zheng Ge
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Acute Myeloid Leukemia
Biomarkers
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08193-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

KK-LC-1 may be an effective prognostic biomarker for gastric cancer

Development and validation of nomograms for predicting axillary non-SLN metastases in breast cancer patients with 1–2 positive sentinel lymph node macro-metastases: a retrospective analysis of two independent cohorts

X-ray repair cross-complementing protein 1 (XRCC1) loss promotes β-lapachone –induced apoptosis in pancreatic cancer cells

Comparison of clinicopathological features and long-term prognosis between mixed predominantly differentiated-type and pure differentiated-type early gastric cancer

Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy

Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer